Dosing begins for COVID-19 Phase I/II trial in Australia
A Phase I/II trial has been launched in Australia by SpyBiotech, a British company, and the Serum Institute of India. The trial has initiated dosing the first patients with the investigational COVID-19 vaccine candidate that will be given to several hundred participants once enrollment is completed. PMLive (UK) (9/11)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!